Drug Trial Radar · NCT04945018
A Study of iPS Cell-derived Cardiomyocyte Spheroids (HS-001) in Patients With Heart Failure (LAPiS Study)
Last checked: Nov 20, 2026Latest source record: Oct 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
10
Actual
Start
Apr 19, 2022
Primary completion
Jul 31, 2025
Study completion Jan 31, 2026
Sponsor
- Lead sponsor
- Heartseed Inc.Industry
- Sponsor type
- Industry
- First posted
- Jun 30, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 20 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this clinical study is to evaluate the safety and efficacy of HS-001 CS transplanted into severe heart failure patients with underlying ischemic heart disease for 26 weeks after transplantation.
Conditions
- Heart Failure
- Ischemic Heart Disease
Interventions
HS-001 CSBiological
Human (allogeneic) iPS-cell-derived cardiomyocyte spheroids suspension
HS-001-D needle, HS-001-D AdaptorDevice
Cardiomyocyte spheroids Dedicated Needles for Implantation and Guided Adaptors
Primary outcomes
What the sponsor says the trial is designed to measure.
- Safety and TolerabilityTime frame: 26 weeks post-transplant
Locations
8 sites in 1 country. Site status is shown where the registry gives one.
St. Marianna University Hospital
Kawasaki, Japan
Saitama Medical University International Medical Center
Saitama, Japan
Juntendo University Hospital
Tokyo, Japan
Nihon University Itabashi Hospital
Tokyo, Japan
The University of Tokyo Hospital
Tokyo, Japan
Tokyo Medical and Dental University Medical Hospital
Tokyo, Japan
Tokyo Metropolitan Geriatric Medical Center
Tokyo, Japan
Tokyo Women's Medical University
Tokyo, Japan
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.